B. Reduced protein expression of LATS1 in glioma. 1: Strong expression of LATS1 in normal brain; 2: Strong expression of LATS1 in glioma WHO grade-1; 3: Strong expression of LATS1 in glioma WHO grade-2; 4: Weak expression of LATS1 in glioma WHO grade-3. 5. Negative expression of LATS1 in glioma WHO grade-4; C. Kaplan–Meier survival analysis of overall survival duration in 103 glioma patients according to LATS1 protein expression. The log-rank test was used to calculate p values. Reduced LATS1 protein expression in glioma We measured the expression levels and subcellular Selleck LGX818 localization of LATS1 protein in archived paraffin-embedded normal brain and glioma samples using learn more immunohistochemical

staining (Figure 1B1-B5). LATS1 protein is primarily localized within the cytoplasm. Furthermore, we observed expression of LATS1 was markedly decreased in glioma samples compared to normal brain tissues (p<0.001) (Table 1). Table 1 The expression of LATS1 protein in Glioma

and normal brain Group   Expression Level of LATS1 Protein(n) P Cases (n) Negative Weak Positive Strong Glioma 103 23 52 20 8   Normal brain 32 1 3 12 16 P<0.001 Relationship between clinicopathologic features and LATS1 expression in glioma patients The relationships between clinicopathologic features and LATS1 expression levels in individuals with glioma were analyzed. We did not find a buy Selonsertib significant association of LATS1

expression levels with patient’s age and sex in 103 glioma cases. However, we observed that the expression level of LATS1 was negatively correlated Flavopiridol (Alvocidib) with WHO grade (P<0.016) and KPS in glioma patients (Table 2). Table 2 The correlation of LATS1 protein expression with Clinicopathological features in Glioma Clinicopathological features Cases (n) Expression Level of LATS1 Protein(n) P Negative Weak Positive Strong Age ≥55 47 11 22 9 5   < 55 56 12 30 11 3 P = 0.752 Gender Male 60 13 35 7 5   Female 43 10 17 13 3 P = 0.326 WHO grade I 19 1 6 8 4   II 22 3 11 6 2   III 30 7 19 3 1   IV 32 12 16 3 1 P<0.001 KPS             ≥80 53 6 28 13 6   <80 50 14 24 7 2 P = 0.011 Survival analysis To investigate the prognostic value of LATS1 expression for glioma, we assessed the association between levels of LATS1 expression and patients’ survival using Kaplan–Meier analysis with the log-rank test. In 103 glioma cases with prognosis information, we observed that the level of LATS1 protein expression was significantly correlated with the overall survival of glioma patients (Figure 2C). Patients with negative and weak level of LATS1 expression had poorer survival than those with positive and strong level of LATS1 expression (P<0.001). In addition, WHO grade and KPS were also significantly correlated with patients’ survival (P<0.001 and P<0.001 respectively).